{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:27:24Z","timestamp":1792153644457,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007700","name":"Universitatea de Medicin\u0103 \u015fi Farmacie \"Carol Davila\" Bucure\u015fti","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.autrev.2024.103670","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T13:49:32Z","timestamp":1731160172000},"page":"103670","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Autoimmunity, a relevant exclusion criterion in the development of mRNA-based compounds: A systematic review of clinical trials registries"],"prefix":"10.1016","volume":"23","author":[{"given":"Larisa","family":"Pinte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Dima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anamaria","family":"Draghici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Caraghiulea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana Andreea","family":"Zamfir-Gradinaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Baicus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2024.103670_bb0005","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.autrev.2024.103670_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-023-46233-6","article-title":"Safety, immunogenicity and efficacy of an mRNA-based COVID-19 vaccine, GLB-COV2-043, in preclinical animal models","volume":"13","author":"Lelis","year":"2023","journal-title":"Sci Rep"},{"issue":"1904776","key":"10.1016\/j.autrev.2024.103670_bb0015","first-page":"190","article-title":"An unstable intermediate carrying information from genes to ribosomes for protein synthesis","volume":"1961","author":"Brenner","year":"1961","journal-title":"Nat"},{"key":"10.1016\/j.autrev.2024.103670_bb0020","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science (80)"},{"key":"10.1016\/j.autrev.2024.103670_bb0025","first-page":"1397","article-title":"Characterization of a messenger RNA polynucleotide vaccine vector","volume":"55","author":"Conry","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.autrev.2024.103670_bb0030","unstructured":"Decades in the Making: mRNA COVID-19 Vaccines|NIAID: National Institute of Allergy and Infectious Diseases. https:\/\/www.niaid.nih.gov\/diseases-conditions\/decades-making-mrna-covid-19-vaccines (accessed 10 Aug 2024)."},{"key":"10.1016\/j.autrev.2024.103670_bb0035","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2024.103670_bb0040","first-page":"13","article-title":"mRNA vaccine in cancer therapy: current advance and future outlook","author":"Li","year":"2023","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.autrev.2024.103670_bb0045","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3390\/life12081254","article-title":"The delivery of mRNA vaccines for therapeutics","volume":"12","author":"Nitika","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.autrev.2024.103670_bb0050","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics \u2014 developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.autrev.2024.103670_bb0055","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines-a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.autrev.2024.103670_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers16050981","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"16","author":"Hato","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.autrev.2024.103670_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/21645515.2024.2307187","article-title":"Recent progress in mRNA cancer vaccines","volume":"20","author":"Yao","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.autrev.2024.103670_bb0070","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/j.vaccine.2024.01.100","article-title":"COVID-19 vaccines and adverse events of special interest: a multinational global vaccine data network (GVDN) cohort study of 99 million vaccinated individuals","volume":"42","author":"Faksova","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.autrev.2024.103670_bb0075","unstructured":"Explained: Why RNA vaccines for Covid-19 raced to the front of the pack|MIT News|Massachusetts Institute of Technology. https:\/\/news.mit.edu\/2020\/rna-vaccines-explained-covid-19-1211 (accessed 10 Aug 2024)."},{"key":"10.1016\/j.autrev.2024.103670_bb0080","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cmi.2023.12.010","article-title":"Comparative safety analysis of mRNA and adenoviral vector COVID-19 vaccines: a nationwide cohort study using an emulated target trial approach","volume":"30","author":"Choi","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.autrev.2024.103670_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0237903","article-title":"A systematic review of trial registry entries for randomized clinical trials investigating COVID-19 medical prevention and treatment","volume":"15","author":"Karlsen","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2024.103670_bb0095","first-page":"11","article-title":"COVID-19 vaccination hesitancy in autoimmune disease patients: policy action and ethical considerations","author":"Shafik","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.autrev.2024.103670_bb0100","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1136\/annrheumdis-2021-221965","article-title":"EULAR 2021 updated viewpoints on SARS-CoV-2 vaccination in patients with RMDs: a guidance to answer patients\u2019 questions","volume":"81","author":"Bijlsma","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103670_bb0105","article-title":"Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis","volume":"376","author":"Bin","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2024.103670_bb0110","first-page":"372","article-title":"Statement: an updated guideline for reporting systematic reviews","volume":"2021","author":"Page","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2024.103670_bb0115","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions|Cochrane Training. https:\/\/training.cochrane.org\/handbook (accessed 10 Aug 2024)."},{"key":"10.1016\/j.autrev.2024.103670_bb0125","author":"ICRTP Registry Network"},{"key":"10.1016\/j.autrev.2024.103670_bb0130","unstructured":"Cochrane Controlled Register of Trials (CENTRAL)|Cochrane Library. https:\/\/www.cochranelibrary.com\/central\/about-central (accessed 21 Jul 2024)."},{"key":"10.1016\/j.autrev.2024.103670_bb0135","unstructured":"Pfizer-BioNTech COVID-19 Vaccine|Pfizer. https:\/\/www.pfizer.com\/products\/product-detail\/pfizer-biontech-covid-19-vaccine (accessed 10 Aug 2024)."},{"key":"10.1016\/j.autrev.2024.103670_bb0145","doi-asserted-by":"crossref","first-page":"726","DOI":"10.7326\/0003-4819-152-11-201006010-00232","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials","volume":"152","author":"Schulz","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2024.103670_bb0150","series-title":"Designing clinical research","author":"Hulley","year":"2013"},{"key":"10.1016\/j.autrev.2024.103670_bb0155","doi-asserted-by":"crossref","unstructured":"Acu\u00f1a-Villaordu\u00f1a A, Baranda JC, Boehmer J, et al. Equitable Access to Clinical Trials: How Do We Achieve It? Published Online First: 5 May 2023. doi:https:\/\/doi.org\/10.1200\/EDBK_389838.","DOI":"10.1200\/EDBK_389838"},{"key":"10.1016\/j.autrev.2024.103670_bb0160","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00296-013-2907-9","article-title":"Comparison of national clinical practice guidelines and recommendations on vaccination of adult patients with autoimmune rheumatic diseases","volume":"34","author":"Papadopoulou","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2024.103670_bb0165","first-page":"29","article-title":"Risk of flare or relapse in patients with immune-mediated diseases following SARS-CoV-2 vaccination: a systematic review and meta-analysis","author":"Shabani","year":"2024","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.autrev.2024.103670_bb0170","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1016\/j.vaccine.2023.05.048","article-title":"Efficacy and safety of mRNA and AstraZeneca COVID-19 vaccines in patients with autoimmune rheumatic diseases: a systematic review","volume":"41","author":"Joudeh","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.autrev.2024.103670_bb0175","doi-asserted-by":"crossref","first-page":"331","DOI":"10.31557\/APJCP.2023.24.1.331","article-title":"Exclusion of patients with autoimmune disease in lung cancer clinical trials","volume":"24","author":"Khan","year":"2023","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.autrev.2024.103670_bb0180","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1002\/cncr.32326","article-title":"To treat or not to treat: patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease","volume":"125","author":"Pantuck","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.autrev.2024.103670_bb0195","first-page":"10","article-title":"The clinical impact of mRNA therapeutics in the treatment of cancers, infections, genetic disorders, and autoimmune diseases","author":"Deyhimfar","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.autrev.2024.103670_bb0200","unstructured":"BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science|BioNTech. https:\/\/investors.biontech.de\/news-releases\/news-release-details\/biontech-publishes-data-novel-mrna-vaccine-approach-treat\/ (accessed 10 Aug 2024)."},{"key":"10.1016\/j.autrev.2024.103670_bb0205","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1126\/science.aay3638","article-title":"A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis","volume":"371","author":"Krienke","year":"2021","journal-title":"Science (80)"},{"key":"10.1016\/j.autrev.2024.103670_bb0210","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/jrsm.1583","article-title":"Impact of searching clinical trials registers in systematic reviews of pharmaceutical and non-pharmaceutical interventions: reanalysis of meta-analyses","volume":"14","author":"Alqaidoom","year":"2023","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.autrev.2024.103670_bb0215","first-page":"1","article-title":"Improving representation in clinical trials and research: building research equity for women and underrepresented groups","author":"Bibbins-Domingo","year":"2022","journal-title":"Improv Represent Clin Trials Res Build Res Equity Women Underrepresent Groups"},{"key":"10.1016\/j.autrev.2024.103670_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-018-0726-5","article-title":"Does information from ClinicalTrials.gov increase transparency and reduce bias? Results from a five-report case series","volume":"7","author":"Adam","year":"2018","journal-title":"Syst Rev"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224001617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224001617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T22:13:23Z","timestamp":1732659203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997224001617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1568997224001617"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103670","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoimmunity, a relevant exclusion criterion in the development of mRNA-based compounds: A systematic review of clinical trials registries","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103670","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103670"}}